Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.

An S De Vriese Rogier CaluwéLotte PyfferoenDirk De BacquerKoen De BoeckJoost DelanoteDidier De SurgeloosePiet Van HoenackerBruno Van VlemFrancis Verbeke

Published in: Journal of the American Society of Nephrology : JASN (2019)

Withdrawal of VKAs and high-dose vitamin K2 improve vitamin K status in patients on hemodialysis, but have no significant favorable effect on VC progression. Severe bleeding complications may be lower with rivaroxaban than with VKAs.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
randomized controlled trial
atrial fibrillation
high dose
venous thromboembolism
pulmonary embolism
newly diagnosed
study protocol
low dose
clinical trial
early onset
risk factors
patient reported outcomes
drug induced